Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.

British journal of clinical pharmacology - 1 Apr 2011

Adam de Beaumais Tiphaine, Fakhoury May, Medard Yves, Azougagh Said, Zhang Daolun, Yakouben Karima, Jacqz-Aigrain Evelyne

Abstract excerpt

AIMS: 6-mercaptopurine (6-MP) is used in the treatment of childhood acute lymphoblastic leukaemia (ALL). Its red blood cell (RBC) metabolite concentrations (6-thioguanine [6-TGN] and 6-methylmercaptopurine nucleotides [6-MMPN]) are related to drug response. We investigated the impact of non-genetic covariates and pharmacogenetic polymorphisms affecting thiopurine methyltransferase (TPMT) and inosine triphosphate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Chemical and Drug Induced Liver Injury

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythrocytes

Share to Mercaptopurine

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Statistics as Topic

Share to Thioguanine

Source

Open in PubMed Open full text

Identifiers

PMID: 21395650
DOI: 10.1111/j.1365-2125.2010.03867.x
PMCID: PMC3080646

Genes

ITPA
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.PMID 21395650Read ↗

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.Semantic proximity Read ↗

Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.Semantic proximity Read ↗

Role of TPMT and ITPA variants in mercaptopurine disposition.Semantic proximity Read ↗

Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase statusSemantic proximity Read ↗

Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.Semantic proximity Read ↗

Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.Semantic proximity Read ↗

Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?Semantic proximity Read ↗

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentSemantic proximity Read ↗

Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.Semantic proximity Read ↗

Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.